SPARC has been used as a biomarker for both diagnosis and prognosis (38) and functions as a sensitizer to chemotherapy by enhancing apoptosis with interfering activity of Bcl-2 (39) in colon cancer. The gene discussed is BCL2; the disease is malignant colon neoplasm.